Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, an intradermal therapeutic vaccine targeting misfolded alpha-synuclein in Parkinson’s disease. The study is evaluating the candidate’s safety and immunogenicity, alongside preliminary biomarkers of efficacy. Top-line results are expected in mid-2027. TRB-001 is designed to generate an immune response against misfolded […]
The post Tridem begins phase Ib trial of Parkinson’s disease vaccine appeared first on Pharmafile.